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the anti-tumour immune response is critical to patient prognosis in colorectal cancer (cRc). the 
aim of this study was to investigate infiltration of B lymphocytes into CRC tumours, and their 
clinical relevance, prognostic value and relation to other immune cell subsets. We used multiplexed 
immunohistochemistry and multispectral imaging to assay the amount of infiltrating CD20+ B 
lymphocytes along with infiltration of CD8+ cytotoxic T cells, FOXP3+ T regulatory cells, CD68+ 
macrophages and CD66b+ neutrophils, in 316 archival CRC tissue specimens. A higher density of 
infiltrating CD20+ B lymphocytes was associated with tumours of the right colon (P = 0.025) and of 
lower stages (P = 0.009). Furthermore, patients whose tumours were highly infiltrated by CD20+ B 
lymphocytes had a significantly improved disease-specific survival (HR = 0.45, 95% CI 0.28–0.73, 
P = 0.001), which remained significant in multivariable analysis. CD20+ B lymphocytes were highly and 
positively associated with CD8+ t lymphocytes (P < 0.001), and part of the prognostic role was found to 
be a cooperative effect between these lymphocyte subsets. Our results support a favourable prognostic 
value of tumour-infiltrating CD20+ B lymphocytes in CRC. Furthermore, a cooperative prognostic effect 
between CD20+ B lymphocytes and CD8+ t lymphocytes is suggested.
Despite medical advances, CRC remains one of the most deadly cancers worldwide1. Curative treatment is 
based on surgical resection, but still almost half of the patients will die of their disease due to tumour metastasis. 
Immune infiltration has been proven to be of powerful prognostic value in CRC2. In the era of immunotherapy, a 
more detailed understanding of how the immune response is organised to counteract tumour growth and spread, 
may lead to important prognostic clues and new targets for therapy.
The adaptive immune response is orchestrated by antigen-specific T and B lymphocytes. T lymphocytes are 
known combaters in anti-tumour immunity and can inhibit tumour growth by direct killing (cytotoxic T lym-
phocytes)3. The prognostic importance of infiltrating subsets of T lymphocytes in CRC has been widely accepted, 
and subsequently led to a joint task force to introduce the Immunoscore, based on immunohistochemical (IHC) 
evaluation of T cell markers, into clinical practice2,4. The role of infiltrating B lymphocytes is less explored and in 
matters of prognostic importance consensus has yet to be reached5. In addition to the adaptive immune response, 
cells of innate immunity are found at the tumour site. Macrophage infiltration has been linked to an improved 
prognosis in CRC6, while the prognostic importance of neutrophils is still uncertain7–10.
Both the intratumoural localisation and functional orientation of immune cells have been shown to carry 
prognostic information. For instance, the strongest prognostic value of the cytotoxic T lymphocytes in CRC 
is found within the tumour epithelium11, while most other immune cell subsets mainly reside in the tumour 
stromal compartment. Infiltration of regulatory T lymphocytes is somewhat surprisingly also associated with 
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an improved prognosis in CRC, but a higher ratio of CD8+ to FOXP3+ cells does appear to improve progno-
sis11–13. Similar trends have been seen when comparing the ratio of tumour infiltrating M1 to M2 subsets of mac-
rophages14. In the Th1/Th2 paradigm, the activity of the cytotoxic T cells is supported by the Th1 lineage and M1 
macrophages, while in contrast regulatory T lymphocytes, B lymphocytes and M2 macrophages are more closely 
related to the tumour promoting Th2 response15. However, coordinated T and B lymphocyte responses are well 
established in both autoimmunity and allograft rejection16,17. In addition, small lymphoid organizations that con-
tain both T and B lymphocytes - called tertiary lymphoid structures (TLS) - are detected in tumours and linked 
to a potent lymphocyte response and a good prognosis, suggesting that the B lymphocytes may collaborate with T 
lymphocytes in anti-tumour immunity18. Towards the goal of developing more efficient therapies, understanding 
the role of B lymphocytes in the immune response to CRC is critical.
In this study, we have used multiplexed IHC and multispectral imaging to analyse the degree of infiltration of 
five different immune cells belonging to both the adaptive (CD20+ B lymphocytes, CD8+ cytotoxic T lympho-
cytes, and FOXP3+ T regulatory cells,) and the innate (CD68+ macrophages and CD66b+ neutrophils) immune 
system, in CRC tissue specimens. By this we could study the individual clinical relevance and prognostic impor-
tance of B lymphocytes, but also the interrelation with other immune cell subsets and their combined prognostic 
value.
Results
Analyses of the distribution of infiltrating immune cells in CRC tumour tissues.  We analysed 
a cohort of 316 CRC patients for local infiltration of immune cell subsets using multiplexed IHC staining and 
multispectral image analysis. Immune cell subsets were identified by sequential staining of CD66b (neutrophils), 
CD8 (cytotoxic T lymphocytes), CD20 (B lymphocytes), CD68 (macrophages) and FoxP3 (T regulatory cells). 
Pan-Cytokeratin was used to identify tumour tissue, and DAPI was used for nuclear counterstaining. Spectral 
unmixing resulted in a composite image displaying the different immune markers (Fig. 1a). Machine-learning 
algorithms were trained for tissue segmentation into different tumour compartments (tumour tissue, stromal 
tissue and no tissue), cell segmentation and cell phenotyping (Fig. 1a) to identify each of the different immune 
markers (Fig. 1b). After exclusions, immune data from 275 patients was collected and presented as number of cells 
per mm2 (Fig. 1c). The exclusion criteria are described in detail in the materials and methods section. In brief, 
36 patients were excluded due to lack of immune data from both TMA cores. For 66 of the 275 study patients, 
immune data was collected from one TMA core. CD8 and CD66b were evident and scored in both tumour and 
stromal compartments, while data from the remaining immune cell markers was collected solely from the stromal 
compartment. Overall, macrophages were found to be the most prominent immune cells infiltrating CRC stromal 
tissues, followed by neutrophils, cytotoxic T lymphocytes, T regulatory cells and B lymphocytes (Fig. 1c). Immune 
infiltration has been vigorously studied in CRC, however the role of B lymphocytes in immune regulation and 
prognosis in CRC is still unclear. We therefore turned our interest to the CD20+ B lymphocyte population.
Relation of infiltrating CD20+ cells to clinical characteristics and other immune cell subsets in 
cRc patients. Tumour infiltrating immune cell subsets were divided into groups of high or low infiltration 
based on the median as a cut-off, and analysed for the associations to patient’s clinical characteristics. CD20+ cells 
were more often highly infiltrating tumours of the right colon (Table 1; P = 0.025) and tumours of lower stages 
(Table 1; P = 0.009). This pattern closely follows that seen for most other immune cell subsets (Supplementary 
Table S2), with the exception of FoxP3, which was not significantly associated with tumour localisation, and 
CD66b, which was not significantly associated with tumour stage. Preoperative radiotherapy was administered 
to 33% of rectal cancers, and irradiated rectal cancers were significantly associated with a reduced infiltration of 
CD20+ cells (Table 1), as well as CD8+ cells and CD66b+ cells (Supplementary Table S2). We found no significant 
associations with age or sex (Table 1). In line with a similar clinical distribution, infiltrating CD20+ cells signifi-
cantly correlated to the presence of all other immune cell subsets analysed, with the strongest correlation to CD8+ 
cells (Table 2).
The prognostic importance of infiltrating CD20+ cells in cRc patients. We next investigated 
the relation of infiltrating CD20+ cells to disease-specific survival in patients with CRC. Patients with tumours 
highly infiltrated by CD20+ cells were found to have an improved prognosis compared to patients with tumours 
poorly infiltrated by CD20 (Fig. 2a). Since radiotherapy was associated with reduced immune infiltration, we 
stratified patients according to preoperative radiotherapy. CD20+ B cells were found to have prognostic value in 
patients with non-irradiated CRC tumours (Fig. 2b), but not in patients with irradiated rectal cancers (Fig. 2c). 
A trend of reduced prognostic value in irradiated patients was seen also for the remaining immune cell subsets 
(Supplementary Table S3). We therefore decided to focus the continued prognostic studies on the patients with 
non-irradiated CRCs.
According to our results, patients with tumours highly infiltrated by CD20+ cells had a significantly improved 
disease-specific survival (Table 3; HR = 0.45, 95% CI 0.28–0.73, P = 0.001), which remained significant in a mul-
tivariable Cox regression model including age, localisation, stage, and stratified by sex (Table 3; HR 0.60, 95% 
CI 0.37‒0.99; P = 0.045). The prognostic value of CD8, CD68 and FoxP3, previously demonstrated in literature, 
was confirmed by our study (Table 3), validating the method used. Our results additionally support a favourable 
prognostic role of CD66b+ cells. For CD8+ cells and CD68+ cells, as well as CD66b+ cells infiltrating the tumour 
compartment, the prognostic value remained in multivariable analysis (Table 3).
The prognostic importance of infiltrating CD20+ cells in relation to other immune cell subsets. 
We next analysed the prognostic importance of CD20+ cells in relation to the other investigated immune cell 
subsets. Since the strongest correlation of infiltrating CD20+ cells was found to CD8+ cells (Table 2), we chose 
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Figure 1. Multispectral imaging of immune cell infiltrates in CRC tissues. (a) A high-magnification area 
(20x) of a representative multiplexed IHC stained composite image after imaging and spectral unmixing (left 
panel), after tissue segmentation into tumour (magenta) and stromal (blue) compartments (middle panel), 
and after cell phenotyping (right panel). The following colors were used to identify the different markers; pan-
Cytokeratin (magenta), CD20 (yellow), CD8 (red), CD66b (green), CD68 (cyan), FoxP3 (orange), and DAPI 
(blue). (b) Illustrates the staining pattern of the individual markers on a high-resolution area of a representative 
TMA core, after spectral unmixing, using the pathology view tool. (c) Histograms displaying the distribution 
(number of cells per mm2) of infiltrating immune cell subsets in the cohort of 275 CRC patients. In addition, the 
normal curve and the median number of infiltrating cells is shown.
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primarily to focus on this interrelationship. To analyse the prognostic importance of CD20+ cells in relation to 
infiltrating CD8+ cells, we compared the prognostic value of groups of CD20 (high or low) to that of CD8 (high or 
low) in the stromal compartment. The best prognosis was found in patients whose tumours were highly infiltrated 
by CD8+ cells (Table 4, Fig. 3a). However, patients with tumours highly infiltrated by both CD8 and CD20 had a 
slightly improved prognosis compared to patients with tumours highly infiltrated by CD8 but poorly infiltrated 
by CD20 (Table 4; P = 0.043; Fig. 3a), suggesting that CD20+ cells may aid in the CD8+ cell mediated anti-tumour 
response. In fact, in patients with tumours poorly infiltrated by CD8+ cells, the prognostic role of CD20 infiltra-
tion was diminished. We found similar relations of CD20 infiltration also to stromal CD66b, CD68 and FoxP3 
infiltration (Table 4; Fig. 3b–d). However, in patients with tumours poorly infiltrated by CD66b, CD68 and FoxP3, 
CD20 infiltration did still appear to have a prognostic advantage (Fig. 3b–d).
Discussion
In this study, we have investigated the prognostic importance of CD20+ B lymphocytes in CRC and their relation 
to other immune cell subsets. Patients with tumours highly infiltrated by CD20+ B lymphocytes were found to 
have an independent prognostic advantage. We further found that the infiltration of CD20+ B lymphocytes was 
highly correlated to infiltration by other immune cell subsets, and that the mere part of the prognostic role of 
CD20+ B lymphocytes likely is mediated through a cooperative effect with the cytotoxic T lymphocytes.
n
Stromal CD20
P-valueLow High
Frequency, n (%) 275 138 (50.2) 137 (49.8)
Mean number of cells/mm2 (±s.d.) 4.4 (±4.8) 255.1 (±516.3)
Age, n (%)
≤59 74 36 (48.6) 38 (51.4) 0.964/0.703*
60–69 73 37 (50.7) 36 (49.3)
70–79 83 41 (49.4) 42 (50.6)
≥80 45 24 (53.3) 21 (46.7)
Sex, n (%)
Women 132 64 (48.5) 68 (51.5) 0.589
Men 143 74 (51.7) 69 (48.3)
Localisation, n (%)
Right-sided colon 73 29 (39.7) 44 (60.3) 0.080/0.025*
Left-sided colon 55 27 (49.1) 28 (50.9)
Rectum 147 82 (55.8) 65 (44.2)
Stage, n (%)
I 55 20 (36.4) 35 (63.6) 0.009/0.009*
II 77 41 (53.2) 36 (46.8)
III 95 44 (46.3) 51 (53.7)
IV 48 33 (68.8) 15 (31.3)
Preoperative radiotherapy†, n (%)
No 227 101 (44.5) 126 (55.5) <0.001
Yes 48 37 (77.1) 11 (22.9)
Table 1. Associations to clinicopathological characteristics. χ2 tests were used for categorical variables. 
*Exact linear-by-linear association test was used to test for linear relationship between variables. †Preoperative 
radiation therapy in rectal cancers only.
Immune marker
CD20 CD20
rs P-value
Stromal CD8 0.568 <0.001
Tumour CD8 0.403 <0.001
Stromal CD66b 0.234 <0.001
Tumour CD66b 0.184 0.002
Stromal CD68 0.219 <0.001
Stromal FOXP3 0.237 <0.001
Table 2. The correlation of infiltration of CD20 positive cells in the stromal compartment to infiltration of other 
immune cell markers. rs, Spearmans rank correlation coefficient. Analyses were performed using continuous 
values for number of cells/mm2 (n = 275).
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We used multiplexed IHC and multispectral imaging to score five different tumour-infiltrating immune cells 
in CRC using well-established markers (CD8+ cytotoxic T lymphocytes, FOXP3+ T regulatory cells, CD20+ B 
lymphocytes, CD68+ macrophages, and CD66b+ neutrophils). CD20 is expressed throughout the different stages 
of B cell development, but is down-regulated upon differentiation into plasma cells19. CD20 is thus a marker 
for naive B cells, germinal center B cells, and memory B cells. The multiplex IHC method is advantageous for 
studies of interrelationships between different immune cell subsets, since it allows immunostaining of multiple 
markers within one image. Multiplex IHC and multispectral imaging has been validated as a good method to 
study tumour immune infiltration in two independent studies, showing reliable data and a good overlap with 
conventional IHC staining and evaluation20,21. The method is not optimal for use on whole tissue sections for 
a large patient cohort, so instead the study was performed using TMA. This together with the chosen digital 
approach has the disadvantage of not being able to assess the often heterogenic distribution of immune cells and 
to avoid e.g. necrotic areas. These problems were partly controlled for by manually inspecting each scanned image 
and when necessary excluding parts or whole images. Furthermore, tumour immune infiltration was calculated 
as a mean value from two individual TMA cores for most patients. An advantage of using a digital approach is, 
however, to overcome observer variability. A weakness of this study is that a large percentage of cases are rectal 
cancers, and that part of these have received preoperative radiotherapy, which may impact immune cell infiltra-
tion. Both reduced and enhanced immune responses are shown in response to irradiation11,22–24. For this reason, 
irradiated rectal cancers were excluded from the survival analyses. However, the effect of irradiation on immune 
infiltration in rectal cancer and the relation to prognosis is interesting, and a topic for further investigation. The 
well-established prognostic value of the different T lymphocyte subsets4,11,13 and macrophages6,25, as previously 
reported in literature using conventional IHC, could be identified also in this study, further strengthening the 
validity of the method used.
Only few studies have explored the prognostic role of B lymphocytes in CRC. The favourable patient prognosis 
seen in our cohort with a high number of tumour-infiltrating CD20+ B lymphocytes is well in line with a previous 
study by Berntsson et al.26, where they in a relatively large cohort found an independent favourable prognostic 
role of infiltrating CD20+ B lymphocytes in CRC primary tumours. In their study, they used a scoring method 
where they manually counted tumour infiltrating CD20+ cells, and analysed their prognostic value by diving 
them into groups of high and low tumour infiltration. In the study by Berntsson et al. they simultaneously showed 
that also infiltration of CD138+ plasma cells was linked to an improved prognosis. They did not however perform 
a combined analysis of B and T lymphocyte infiltrates. Two more studies have addressed the prognostic role of 
CD20+ B lymphocytes in CRC and found a neutral or negative prognostic role27,28. These were smaller studies 
Figure 2. Disease-specific survival in CRC according to infiltration of CD20+ cells. High or low infiltration of 
stromal CD20 in CRC cases (a), in non-irradiated CRC cases (b), and in irradiated rectal cancers (c). Shown are 
Kaplan-Meier plots. Log-rank tests were used to calculate P-values.
Immune marker
univariable multivariablea
HR 95% CI P-value HR 95% CI P-value
Stromal CD20 0.45 0.28–0.73 0.001 0.60 0.37–0.99 0.045
Stromal CD8 0.32 0.20–0.53 <0.001 0.42 0.25–0.72 0.002
Tumour CD8 0.31 0.19–0.51 <0.001 0.54 0.33–0.90 0.018
Stromal CD66b 0.60 0.38–0.96 0.033 0.73 0.45–1.17 0.189
Tumour CD66b 0.47 0.29–0.75 0.002 0.56 0.34–0.92 0.022
Stromal CD68 0.38 0.23–0.62 <0.001 0.55 0.31–0.96 0.034
Stromal FoxP3 0.31 0.19–0.51 <0.001 0.75 0.43–1.31 0.318
Table 3. Cox regression analyses of infiltrating immune cells in predicting survival of CRC patients. aThe Cox 
regression multivariable models included one categorical immune parameter, age, localisation and stage, and 
were stratified by sex (n = 217). Abbreviations: HR, hazard ratio; CI, confidence interval.
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using a semi-quantitative scale of infiltration, which may contribute to these differences. Our study reinforces a 
positive prognostic role of B lymphocytes in primary CRC. Infiltration by CD20+ B lymphocytes in metastatic 
CRC has been explored, and also here a beneficial impact on prognosis has been found29,30.
We further addressed the prognostic relation of infiltrating CD20+ B lymphocytes with the other immune 
cell subsets. A high infiltration of CD20+ B lymphocytes was found to slightly increase the prognostic effect of 
CD8+ cytotoxic T lymphocytes, while having no prognostic effect on patients with tumours poorly infiltrated by 
CD8+ cytotoxic T lymphocytes. A finding suggesting a cooperative prognostic effect between these lymphocyte 
subsets, which to our knowledge has not previously been shown in primary CRC. The combined prognostic 
value of CD8+ and CD20+ lymphocytes has been previously addressed in one study on metastatic CRC, where a 
combined additive effect was shown when both immune cell subsets were present30. Similarly, combined effects 
by T and B lymphocyte infiltration has been suggested for ovarian cancer, hepatocellular carcinoma, and pancre-
atic ductal adenocarcinoma31–33. Our study showed additive prognostic effects of CD20+ B lymphocytes also for 
CD66b+ neutrophils, CD68+ macrophages and FoxP3+ T regulatory cells, which may indicate interrelationships 
also between these immune cell subtypes. However, here the prognostic effect of CD20 was not entirely depend-
ent on infiltration by these other immune cell subsets. Further studies are needed to evaluate these possible 
interactions.
There are several ways by which T and B lymphocytes may theoretically interact in anti-tumour immunity. B 
lymphocytes do produce cytokines that could support the T cell response. They may also act as antigen-presenting 
cells to T cells, and produce antibodies directed against tumour antigens. B lymphocyte-derived antibodies have 
been shown to recognize tumour antigens in CRC34, as well as e.g. lung and breast cancer35,36. Interestingly, the B 
lymphocytes were often, but not always, found in lymphoid-like follicles denoted TLS, and the presence of TLS 
have been linked to an improved prognosis in many cancers including CRC18. In CRC, a strong co-localisation 
of CD20 and Ki67 was additionally found within TLS, suggestive of B lymphocyte proliferation and tumour 
reactivity37. On the other hand, there are mouse data that instead hint towards a potential negative effect of 
tumour-infiltrating B cells in CRC38. At present, the role of B lymphocytes in the anti-tumour immune response 
and as a clinical parameter to predict outcome remains unclear. Future studies, taking into account also the phe-
notype and function of different B lymphocyte subsets, are needed. Further understanding of the interactions 
within the anti-tumour immune response may provide prognostic clues and additional tools for immunotherapy.
In conclusion, the results of our study support a positive prognostic role of tumour-infiltrating CD20+ B 
lymphocytes in CRC patients. Furthermore, a cooperative prognostic effect between CD20+ B lymphocytes and 
cytotoxic T lymphocytes is suggested.
Materials and Methods
Patient cohort and TMAs.  The study population consisted of 316 CRC patients operated on in the years 
1998–2003 in the Department of Surgery, Helsinki University Hospital. Actual survival data was provided by the 
Finnish Population Register Center, and cause of death was specified by Statistics Finland. The median age at 
diagnosis was 69 years. The study was approved by the Surgical Ethics Committee of Helsinki University Hospital 
(Dnro HUS 226/E6/06, extension TMK02 §66 17.4.2013) and in accordance with relevant guidelines and regula-
tions. The National Supervisory Authority of Welfare and Health gave us permission to use tissue samples without 
the individual informed consent of the patients in this retrospective study (Valvira Dnro 10041/06). For con-
struction of tissue microarray (TMA) blocks an experienced gastropathologist annotated representative tumour 
Immune marker n
univariable multivariablea
HR 95% CI P-value HR 95% CI P-value
Stromal CD20/
Stromal CD8
High/High (ref) 97 1.00 — <0.001 1.00 — 0.007
High/Low (1) 29 3.83 1.85–7.95 <0.001 3.36 1.54–7.34 0.002
Low/High (2) 33 2.28 1.03–5.08 0.043 2.05 0.91–4.61 0.084
Low/Low (3) 68 4.06 2.20–7.48 <0.001 2.87 1.49–5.51 0.002
Stromal CD20/
Stromal CD66b
High/High (ref) 76 1.00 — 0.002 1.00 — 0.157
High/Low (1) 50 1.55 0.75–3.21 0.240 1.54 0.73–3.24 0.259
Low/High (2) 49 2.11 1.07–4.15 0.031 1.86 0.92–3.78 0.086
Low/Low (3) 52 3.37 1.76–6.43 <0.001 2.13 1.09–4.14 0.027
Stromal CD20/
Stromal CD68
High/High (ref) 73 1.00 — <0.001 1.00 — 0.018
High/Low (1) 53 3.45 1.57–7.58 0.002 3.27 1.41–7.59 0.006
Low/High (2) 44 2.96 1.28–6.83 0.011 3.32 1.40–7.87 0.006
Low/Low (3) 57 5.59 2.64–11.82 <0.001 3.38 1.49–7.67 0.004
Stromal CD20/
Stromal FoxP3
High/High (ref) 74 1.00 — <0.001 1.00 — 0.194
High/Low (1) 52 3.10 1.46–6.57 0.003 1.34 0.60–3.02 0.476
Low/High (2) 43 2.03 0.90–4.61 0.089 1.74 0.74–4.08 0.201
Low/Low (3) 58 5.80 2.91–11.58 <0.001 2.11 0.99–4.50 0.053
Table 4. Prognostic relations of immune cell subsets in CRC. aThe Cox regression multivariable models 
included one categorical immune parameter, age, localization and stage, and were stratified by sex. 
Abbreviations: HR, hazard ratio; CI, confidence interval.
7Scientific RepoRtS |         (2019) 9:19997  | https://doi.org/10.1038/s41598-019-56441-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
areas on H&E slides. The TMA blocks were constructed using a TMA Grand Master 3D instrument (Histech Ltd 
Budapest, Hungary) by punching 1 mm cores from archived formalin-fixed and paraffin-embedded (FFPE) tissue 
samples. The TMA used for this study included two 1 mm cores taken within the tumour mass, one more central 
and one more peripheral to avoid systematic heterogeneity
Multiplexed immunohistochemical (iHc) staining. Multiplexed IHC staining was modified from 
the manufacturer´s instructions to the OpalTM 7 Solid Tumour Immunology Kit (PerkinElmer, Waltham, MA, 
USA), but optimized for colorectal FFPE TMA tissue sections. In brief, tissue TMA slides were sequentially 
stained using antibodies against CD66b, CD8, CD20, FoxP3, CD68 and pan-Cytokeratin. The CD4 antibody 
used in the kit was exchanged by CD66b (clone 80H3, LsBio, Seattle, WA, USA). The CD8 antibody in the kit was 
exchanged by CD8 (clone 144b, DAKO). Concentrations of antibodies and Opal dyes were adjusted (according 
to Supplementary Table S1) so that the signal intensity of each marker would allow exposure times of 30–200 ms 
and a signal range of 5–30 ms. Slides were mounted using Prolong Diamond Antifade Mountant (ThermoFisher, 
Waltham MA, USA).
Multispectral imaging. Imaging was performed using the VECTRA 3 Quantitative Pathology Imaging 
System (PerkinElmer). All standard epi-flourescent filters were used; DAPI, FITC, CY3, Texas Red, and CY5. 
Whole slide scans were acquired using x10 magnification. The Phenochart software (PerkinElmer) was subse-
quently used to mark TMA cores from the whole slide scans for subsequent multispectral imaging using x20 
magnification. A spectral library was collected by single stainings of colorectal FFPE tissue sections with the CD20 
antibody and the individual Opal dyes and subsequent imaging. An unstained sample was used as autofluorescence 
control and utilized together with the spectral library for spectral unmixing in the inForm software (PerkinElmer). 
Composite images were compared to single stained slides and inspected for crosstalk and interference.
image analysis and data collection. Images were quantified using the inForm software in two steps. 
Firstly, 15 TMA cores representing the heterogeneous nature of CRC, were selected to train machine-learning 
algorithms for tissue segmentation, cell segmentation and cell phenotyping, that were later applied on the whole 
TMA cohort. The software was first trained to segment tissue by manually annotating tumour tissue, stromal 
Figure 3. Prognostic relation of CD20+ cells to different immune cell subsets in CRC. Cases scored for 
subgroups of CD20 high or low together with; (a) CD8 high or low; (b) CD66b high or low; (c) CD68 high or 
low; and (d) FoxP3 high or low, in the tumour stromal compartment as indicated. Shown are Kaplan-Meier 
plots. Log-rank tests were used to calculate P-values.
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tissue, and no tissue, according to manufacturer´s recommendations. Cell segmentation was based on the nuclear 
DAPI stain, but assisted using nuclear FoxP3, and membrane CD8, CD66b, CD20 and CD68 staining. For classifi-
cation of cell phenotypes, the software was trained by manually annotating 34–72 cells identified by each marker. 
Each scanned image was examined by one observer under the supervision of an experienced gastropathologist. 
Exclusion criteria for whole TMA cores were; loss of large part or whole core (n = 33), lack of tumour or stromal 
tissue (n = 32), bad quality of staining (e.g. weak pan-Cytokeratin stain) (n = 42), and heavy necrosis (n = 24). In 
total, this lead to the exclusion of 5 patients due to large part or whole cores lost, 3 patients due to lack of tumour 
or stromal tissues, 10 patients due to bad quality of staining, 5 patients due to heavy necrosis, and 13 patients 
were excluded for a mixture of the above described exclusion criteria. Four of the remaining patients had dupli-
cate TMA sets, and for these patients the immune infiltration was calculated from all available TMA cores. One 
patient was excluded due to lack of clinical information. After exclusions, 275 patients remained in the study, of 
which 209 had immune data from two or more cores, and 66 had immune data from one TMA core.
We inspected each TMA core for areas of disinterest, which were manually drawn and subtracted from the 
image. Exclusion areas included; cellular debris, mucus, large vessels, areas of necrosis, large lymphoid aggregates 
and normal epithelial tissue. After exclusion of cores and regions, cell segmentation summary data was collected 
for each TMA core, and converted to number of individual cell types per mm2 (tumour or stromal compartment). 
For patients with data on two TMA cores, an average number of cells per mm2 was calculated from the total num-
ber of cells divided by the total tissue area. Infiltrating immune cells, as identified by the different markers, were 
further divided into groups of high and low infiltration by the median number of infiltrating cells.
Statistics. Statistical analyses were performed using PASW Statistics 25 (SPSS Inc., Chicago, IL, USA). The χ2 
test was used for cross-tabulations and the linear-by-linear association test for linear relationships. Correlations 
between continuous variables were analysed using the Spearman´s rank correlation test. Disease-specific survival 
was estimated using Kaplan-Meier survival analysis, and comparisons of differences in outcome between groups 
were analysed using the log-rank test. Multivariable survival analyses were performed using Cox proportional 
hazard models. Testing of the Cox model assumption of constant hazard ratios over time involved the inclusion 
of a time-dependent covariate separately for each testable variable. There was weak indication that gender did 
not follow the assumption, therefore, in multivariable analyses, a stratified analysis for gender was performed. 
Interaction terms were considered, but no significant interaction was found after the Bonferroni correction for 
multiple testing. P < 0.05 was considered statistically significant.
Data availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.
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